Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
04 janv. 2022 08h00 HE
|
Protara Therapeutics
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview
04 nov. 2021 08h00 HE
|
Protara Therapeutics
– TARA-002 Confirmatory Large-Scale GMP Comparability Complete – – U.S. FDA Cleared the Company’s IND Application for TARA-002 in NMIBC; Company Plans to Initiate Phase 1 Clinical Trial by Year-End –...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 oct. 2021 16h45 HE
|
Protara Therapeutics
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
12 oct. 2021 07h00 HE
|
Protara Therapeutics
- Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End - - IND Application Included Submission of Confirmatory Large-Scale GMP Comparability Data - NEW YORK, Oct. 12, 2021 (GLOBE...
Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
17 sept. 2021 16h05 HE
|
Protara Therapeutics
NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition
13 sept. 2021 07h00 HE
|
Protara Therapeutics
-Study found that approximately 30% of patients who are dependent on parenteral nutrition have cholestasis- -Results support significant unmet medical need in patients dependent on parenteral...
Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 08h00 HE
|
Protara Therapeutics
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview
05 août 2021 08h00 HE
|
Protara Therapeutics
- Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End - - TARA-002 GMP Scale up and Comparability Ongoing and Expected to...
Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
07 juil. 2021 08h00 HE
|
Protara Therapeutics
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors
10 juin 2021 08h00 HE
|
Protara Therapeutics
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...